Isthmus Partners LLC Invests $1.37 Million in Hologic, Inc. (HOLX)

Isthmus Partners LLC purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 205,829 shares of the medical equipment provider’s stock, valued at approximately $1,371,000. Isthmus Partners LLC owned approximately 0.07% of Hologic at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Oregon Public Employees Retirement Fund boosted its position in shares of Hologic by 3,960.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 1,192,649 shares in the last quarter. Lindbrook Capital LLC acquired a new stake in shares of Hologic during the 4th quarter worth approximately $36,000. Essex Savings Bank acquired a new stake in shares of Hologic during the 4th quarter worth approximately $37,000. Cerebellum GP LLC acquired a new stake in shares of Hologic during the 4th quarter worth approximately $43,000. Finally, Clean Yield Group acquired a new stake in shares of Hologic during the 4th quarter worth approximately $47,000. 90.39% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Peter J. Valenti III sold 4,242 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $47.38, for a total transaction of $200,985.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Sally Crawford sold 12,306 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $47.61, for a total transaction of $585,888.66. Following the transaction, the director now owns 168,886 shares in the company, valued at $8,040,662.46. The disclosure for this sale can be found here. Insiders sold 23,378 shares of company stock valued at $1,105,836 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research note on Thursday. TheStreet downgraded shares of Hologic from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. BTIG Research reissued a “buy” rating and issued a $52.00 price objective on shares of Hologic in a research note on Thursday, May 2nd. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price objective (up previously from $50.00) on shares of Hologic in a research note on Thursday, May 2nd. Finally, BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. Hologic presently has an average rating of “Hold” and a consensus target price of $45.41.

NASDAQ:HOLX opened at $45.60 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $12.20 billion, a price-to-earnings ratio of 20.45, a P/E/G ratio of 2.10 and a beta of 0.71. Hologic, Inc. has a 12 month low of $37.47 and a 12 month high of $48.82.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.01. The business had revenue of $818.40 million during the quarter, compared to analysts’ expectations of $806.99 million. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The business’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the company posted $0.53 earnings per share. As a group, research analysts anticipate that Hologic, Inc. will post 2.42 EPS for the current year.

WARNING: “Isthmus Partners LLC Invests $1.37 Million in Hologic, Inc. (HOLX)” was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/12/isthmus-partners-llc-acquires-new-stake-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: What is a growth and income fund?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.